Duramed's Phelps is more sanguine. As a stockholder you feel that FDA pulled the rug out from under us. There's a sense that you invested based on the best advice of the government, and then you lost because of the process. But as a scientist, you learn something every day . . . The best understanding holds until you learn something new.
Woodcock is sympathetic but firm.
Meanwhile, the science had changed quite a bit, and our knowledge of estrogens and receptors increased. . . . Lessons learned As with all facets of drug discovery, the science marches on. And although the controversy over Premarin has been painful for both the industry and the FDA, it may yet bear fruit. And, a more intricate understanding of estrogens could assist in the fight against estrogen-responsive forms of breast cancer. In 1995, researchers discovered a second estrogen receptor in rats, ER-b.